Research on ipamorelin, a selective growth hormone secretagogue peptide, in pituitary signaling and metabolic studies.
Also called Ipamorelin, IPAM, growth hormone secretagogue
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Ipamorelin is an emerging peptide supplement and growth hormone secretagogue intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.1
Ipamorelin is increasingly encountered in clinical practice, urology, sexual medicine, and online self-administration protocols.12 The adoption of this peptide is often influenced by off-label prescribing and direct-to-consumer promotion.2 It is frequently perceived as low risk by patients and athletes, despite the absence of efficacy or safety data for musculoskeletal tissue recovery in animal and human models.3 Reported adverse effects associated with performance-enhancing peptides modulating this axis span fluid retention syndromes, injection-site reactions, musculoskeletal symptoms, and endocrine and metabolic disturbances.1
CRISPR/Cas9-mediated PD-L1 knockout reshapes temporal transcriptomic responses to PRRSV infection in porcine alveolar macrophages
PLoS ONE — Sheet S — Nov 2026
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
Sexual Medicine Reviews — Vasylieva V — Sep 2026
Designing a provider-led multimorbidity care model for fragmented insurance-based health systems: A mixed-methods study in Colombia
PLoS ONE — Valencia O — Sep 2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
The American Journal of Sports Medicine — Tewari K — Aug 2026
A Secondary, Subgroup Analysis of Alcohol Cue‐Exposure Craving in Response to Pharmacological Inhibition of the Growth Hormone Secretagogue Receptor With <scp>PF</scp> ‐5190457
Alcohol Clinical and Experimental Research — Tyler R — Jun 2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology — Dominikowski A — Jun 2026
Activation of the nucleus nuclear factor erythroid 2-related factor 2 via ghrelin/growth hormone secretagogue receptor 1a signaling by Yueju pill (越鞠丸) confers cardioprotective and antidepressant effects
JING Y — Jun 2026
Research Peptides for Sale: Quality Standards for BPC-157, TB-500, Sermorelin and Epitalon Procurement
Research E — May 2026
Integrated Pediatric Adaptation Model - A Translational framework for Neuro-Developmental excellence in early Childhood Education
Luongo V — May 2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
JBJS Reviews — Meza A — May 2026
LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
Cell Reports Medicine — Hagemann C
86 citations · 2022 · among the most cited on Ipamorelin
Molecular Mechanisms and Health Benefits of Ghrelin: A Narrative Review
Nutrients — Jiao Z
83 citations · 2022 · among the most cited on Ipamorelin
LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue
Molecular Metabolism — Shankar K
81 citations · 2021 · among the most cited on Ipamorelin
The ups and downs of growth hormone secretagogue receptor signaling
FEBS Journal — Cornejo M
48 citations · 2021 · among the most cited on Ipamorelin
LEAP2 Impairs the Capability of the Growth Hormone Secretagogue Receptor to Regulate the Dopamine 2 Receptor Signaling
Frontiers in Pharmacology — Mustafá E
41 citations · 2021 · among the most cited on Ipamorelin
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.